Zura Bio Limited has recently unveiled positive results from a Phase 1 trial of its leading drug candidate, tibulizumab (ZB-106), aimed at treating Sjogren’s syndrome.

Genentech's Phase III STARGLO Trial Shows Columvi Significantly Prolongs Survival in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.

KSQ Therapeutics Begins Clinical Trials with Initial Patient Dosed for CRISPR/Cas9 Modified eTIL® Therapy KSQ-001EX.

Avidity Reveals Remarkable Phase 1/2 FORTITUDE™ Trial Results for AOC 1020 Showing Over 50% Decrease in DUX4 Genes and Functional Improvement Trends in Facioscapulohumeral Muscular Dystrophy Patients.

Zumutor Biologics Inc. has recently disclosed that the initial patient has been treated in its Phase 1 clinical trial with ZM008.

Nektar Therapeutics Unveils Initial Preclinical Findings on NKTR-0165, a TNFR2 Agonist Antibody for Inflammatory Disease Therapy, at EULAR 2024.

Vivani Medical Reports FDA Approval of New Drug Application and Removal of Clinical Hold for NPM-119, a Mini Subdermal GLP-1 Implant.

The FDA has approved Kevzara® (sarilumab) for treating active polyarticular juvenile idiopathic arthritis (pJIA).

Ipsen's Iqirvo® gets expedited U.S. FDA approval as an innovative PPAR therapy for primary biliary cholangitis.

NMD Pharma A/S announced today that it has administered the first dose to a patient with generalized myasthenia gravis in a Phase 2b clinical trial of NMD670.

Alvotech and STADA are expanding their joint efforts to include AVT03, a biosimilar candidate in clinical development that uses Prolia/Xgeva (denosumab) as reference drugs aimed at treating osteoporosis and cancer-induced bone deterioration.

Assembly Biosciences, has reported that the initial participant has received a dose in the Phase 1a/b clinical trial of its long-acting herpes simplex virus helicase-primase inhibitor, ABI-5366.